Ironwood Hits Endpoints In GERD, But Analysts Unimpressed With Treatment Effect
Executive Summary
The GI specialty firm hopes it has a future blockbuster with the bile acid sequestrant after hitting multiple endpoints in Phase IIb, but the treatment effect compared to PPI therapy alone was below what was previously anticipated.
You may also be interested in...
Commercial Capsules: Q2 Reporters, Mitsubishi Buy, Celltrion IPO, Renflexis Launch, Keytruda Fail, Ironwood and Vertex Trial Results
Q2 reporting is on a roll as GSK unveils a major shake-up under new CEO Walmsley; the prospect of a simplified route to approval may have helped Neuroderm secure Mitsubishi take-out; biosimilar developments include Celltrion Healthcare's IPO and Merck & Co's launch of Renflexis in the US; clinical trial updates were reported for Keytruda, Ironwood's GERD candidate and Vertex's next generation of cystic fibrosis candidates. Commercial Capsules rounds up key commercial news reported recently by sister publication Scrip.
Commercial Capsules: Q2 Reporters, Mitsubishi Buy, Celltrion IPO, Renflexis Launch, Keytruda Fail, Ironwood and Vertex Trial Results
Q2 reporting is on a roll as GSK unveils a major shake-up under new CEO Walmsley; the prospect of a simplified route to approval may have helped Neuroderm secure Mitsubishi take-out; biosimilar developments include Celltrion Healthcare's IPO and Merck & Co's launch of Renflexis in the US; clinical trial updates were reported for Keytruda, Ironwood's GERD candidate and Vertex's next generation of cystic fibrosis candidates. Commercial Capsules rounds up key commercial news reported recently by sister publication Scrip.
Ironwood Could Use Linzess As Model For GERD Market
The biotech has moved into mid-stage studies with a heartburn drug that will face OTC competition, much like Linzess has battled with in the area of constipation.